Details of a Researcher - Torii, Hidemasa

Papers - Torii, Hidemasa

Division display 61 - 80 of about 210 ／ All the affair displays >>

臨床: 多焦点眼内レンズ関連3編

Kizawa Junya, Torii Hidemasa, Nagata Mayumi

The Journal of The Japanese Society for Cataract Research (The Japanese Society for Cataract Research) 34 ( 1 ) 85 - 86 2022

Lead author, Last author, Corresponding author, ISSN 09154302

Ginkgo biloba Extracts Showed Myopia Suppressive Effects in a Lens-Induced Myopia Model in Mice

J Hou, K Mori, S Ikeda, H Jeong, H Torii, K Negishi, T Kurihara, K Tsubota

Investigative Ophthalmology & Visual Science 63 (7), 1452–F0410-1452–F0410 2022

Lead author, Last author, Corresponding author

Lipidomic analysis revealed n‐3 polyunsaturated fatty acids suppressed choroidal thinning and myopia progression in mice

K Mori, S Kuroha, J Hou, H Jeong, M Ogawa, S Ikeda, JX Kang, K Negishi, ...

The FASEB Journal 36 (6), e22312 2022

Lead author, Last author, Corresponding author

Intensive outdoor activity for 1 week increased choroidal thickness

M Ogawa, H Torii, E Yotsukura, K Mori, A Hanyuda, J Matsumura, ...

Investigative Ophthalmology & Visual Science 63 (7), 246–A0100-246–A0100 2022

Lead author, Last author, Corresponding author

有水晶体眼内レンズ挿入後眼の白内障手術における眼内レンズ度数計算精度

菅原薫子, 鳥居秀成, 増井佐千子, 重野雄太, 西恭代, 四倉絵里沙, 根岸一乃

IOL & RS ((株)杏林舎内「IOL&RS」編集事務局) 35 ( 4 ) 632 - 638 2021.12

Lead author, Last author, Corresponding author, ISSN 1341-3678

目的:有水晶体眼内レンズ挿入後眼の白内障手術における眼内レンズ(IOL)度数計算精度を検討する。対象と方法:対象は慶應義塾大学病院にて、有水晶体IOL挿入後眼の白内障手術を行い、術後1ヵ月以上経過観察できた9例12眼(平均年齢52.3歳)で、Hill-RBF 2.0(Hi)、Barrett-Universal II(Ba式)、Haigis(Ha式)、SRK/T(S式)による術後屈折誤差(術後予測屈折値と術後1ヵ月の自覚等価球面値の差)を後方視的に比較した。結果:挿入されたIOLはDCB00/DCB00V(Johnson & Johnson、D群)が6例8眼(平均眼軸長27.62mm)、MA60MA(Alcon、M群)が3例4眼(平均眼軸長31.25mm)であった。術後屈折誤差は算術値、絶対値ともに両群とも各計算法間で有意差を認めなかった。術後屈折誤差が±0.5D以内の割合(%)は、D群ではHi、Ba式、Ha式、S式の順に85.7、50.0、37.5、50.0、M群では75.0、75.0、50.0、50.0であり、±1.0D以内の割合(%)は、D群ではいずれの計算法でも100.0、M群では100.0、100.0、75.0、75.0であった。結論:Hiは、有水晶体IOL挿入後眼の白内障手術におけるIOL度数計算法として4つの中で最も有用である可能性が示唆された。(著者抄録)

Effect of violet light-transmitting eyeglasses on axial elongation in myopic children: a randomized controlled trial

K Mori, H Torii, Y Hara, M Hara, E Yotsukura, A Hanyuda, K Negishi, ...

Journal of clinical medicine 10 (22), 5462 (Journal of Clinical Medicine) 10 ( 22 ) 2021.11

Lead author, Last author, Corresponding author, ISSN 2077-0383

The fact that outdoor light environment is an important suppressive factor against myopia led us to invent violet light-transmitting eyeglasses (VL glasses) which can transmit violet light (VL), 360–400 nm in wavelength, for the suppression of myopia, and can meanwhile block harmful ultra-violet waves from sunlight. The current study is a double-blinded randomized clinical trial to investigate the myopia-suppressive effect of VL glasses compared to conventional eyeglasses (placebo glasses) that do not transmit VL. The subjects were children aged from 6 to 12 years old, the population in which myopia progression is generally accelerated, and the myopia suppressive effect was followed up for two years in a city in Japan. Periodical ophthalmic examinations, interviews, and measurements of reflection and axial length under mydriasis were performed at the initial visit (the baseline) and at 1, 6, 12, 18, and 24 months. The mean change in axial length in the VL glasses group was significantly smaller than in the placebo glasses group when time for near-work was less than 180 min and when the subjects were limited to those who had never used eyeglasses before this trial (p < 0.01); however, this change was not significant without subgrouping. The suppressive rate for axial elongation in the VL glasses group was 21.4% for two years.

Access to Document (DOI)

Corrigendum to Ratio of Axial Length to Corneal Radius in Japanese Patients and Accuracy of Intraocular Lens Power Calculation Based on Biometric Data. Am J Ophthalmol 2020;218:320-329.

Omoto MK, Torii H, Hayashi K, Ayaki M, Tsubota K, Negishi K

American journal of ophthalmology (American Journal of Ophthalmology) 231 210 2021.11

Lead author, Last author, Corresponding author, ISSN 0002-9394

Access to Document (DOI)

増刊号この症例このまま診ていて大丈夫?　病診連携にもとづく疾患別眼科診療ガイド 4　白内障眼内レンズ交換

鳥居秀成

臨床眼科 (株式会社医学書院) 75 ( 11 ) 159 - 166 2021.10

Lead author, Last author, Corresponding author, ISSN 03705579

Clinical outcomes of KeraVio using violet light: emitting glasses and riboflavin drops for corneal ectasia: a pilot study

H Kobashi, H Torii, I Toda, S Kondo, M Itoi, K Tsubota

British Journal of Ophthalmology 105 (10), 1376-1382 (British Journal of Ophthalmology) 105 ( 10 ) 1376 - 1382 2021.10

Lead author, Last author, Corresponding author, ISSN 0007-1161

Background/aims We developed a novel technology consisting of violet light (VL)-emitting glasses and defined the combination of VL irradiation and riboflavin treatment as KeraVio. Our goal was to evaluate the clinical results of KeraVio in patients with progressive corneal ectasia. Methods Eyes were exposed to VL (375 nm, irradiance 310 μW/cm 2)-emitting glasses for 3 hours daily for 6 months, and a riboflavin solution was administered onto the corneal epithelium six times during each 3-hour VL irradiation. The primary end point was a change in the maximum keratometry (Kmax) value over 6 months compared with that over the 1 year before baseline. Results The efficacy of KeraVio was evaluated in 20 eyes with severe progression, and its safety was evaluated in all 40 eyes. The mean changes in Kmax over the 1 year before baseline and during the 6-month observation period were 6.03±3.41 dioptres (D) and -0.81±3.34 D, respectively (p=0.002). At 6 months, the Kmax value decreased by more than 2 D in 4 eyes (20%), remained within 2 D in 13 eyes (65%), and increased by 2 D or more in 3 eyes (15%). The corneal stromal demarcation line was identified in 16 eyes (80%), and its depth was 206.3±54.9 μm at 1 month. No significant decrease in endothelial cell density, lenticular opacity or transient corneal haze was noted. Conclusion Based on our 6-month results, daily treatment of progressive corneal ectasia with KeraVio can halt disease progression without any safety concerns. Clinical trial registration number jRCTs032180217.

Access to Document (DOI)

Association between ocular axial length and anthropometrics of Asian adults

A Shinojima, T Kurihara, K Mori, Y Iwai, A Hanyuda, K Negishi, H Torii, ...

BMC Research Notes 14, 1-5 (BMC Research Notes) 14 ( 1 ) 328 2021.08

Lead author, Last author, Corresponding author

Objective: The purpose of this study is to analyze axial length, body height, hand length, and foot length to find new factors that predict myopia and to identify gender differences as one of the factors of high myopia. A cross-sectional study was conducted as a single observation. Body height, hand length, and foot length were measured according to standard anthropometric methods. Axial length, retinal thickness, and choroidal thickness were measured using the IOL Master 700 and the Heidelberg Spectralis-OCT. To account for body height differences among participants, foot length/body height and hand length/body height were analyzed using a mixed-effects model. Results: A total of 80 eyes (men, n = 20, 40 eyes; women, n = 20, 40 eyes) were analyzed. The mean age was 33.5 years (range 21–59 years, SD: 9.6). For choroidal thickness, there was a significant association with axial length in men (p < 0.001) and a trend toward an association in women (p = 0.072). There was also a significant association between foot length/body height and axial length in men (p = 0.015), but not in women (p = 0.58). These results suggest that factors that determine body height and foot length may be related to axial length, although they vary by gender.

Access to Document (DOI)

Short-term efficacy and safety of cataract surgery combined with iris-fixated phakic intraocular lens explantation: A multicentre study

MK Omoto, H Torii, S Masui, M Ayaki, I Toda, H Arai, T Nakamura, ...

Journal of Clinical Medicine 10 (16), 3672 (Journal of Clinical Medicine) 10 ( 16 ) 2021.08

Lead author, Last author, Corresponding author, ISSN 2077-0383

The purpose of this study was to evaluate the short-term efficacy and safety of cataract surgery for patients with iris-fixated phakic intraocular lenses (pIOLs). This study included 96 eyes of 91 patients. The changes in the logMAR uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), subjective spherical equivalent (SE), astigmatism, and endothelial cell density (ECD) were collected retrospectively. The intraoperative and postoperative complications also were investigated to assess the surgical safety. The preoperative UCVA and BCVA improved significantly at month 1 postoperatively, respectively (p <0.001 for both comparisons). The efficacy and safety index at month 1 postoperatively were 1.02 ± 0.56 and 1.31 ± 0.64, respectively. The SE at month 1 postoperatively was significantly (p <0.001) higher compared to preoperatively, whereas the subjective astigmatism did not differ significantly (p = 0.078). The ECD significantly decreased at month 1 (p < 0.001). The most common postoperative complication was intraocular pressure elevation exceeding 25 mmHg in 10.4% of eyes, which was controlled with medications in all cases until month 1 postoperatively. No intraoperative complications developed. Cataract surgeries for patients with iris-fixated pIOLs were performed safely with good visual outcomes.

Access to Document (DOI)

Violet light suppresses lens-induced myopia via neuropsin (OPN5) in mice

Jiang Xiaoyan, Pardue Machelle T., Mori Kiwako, Ikeda Shin-ichi, Torii Hidemasa, D'Souza Shane, Lang Richard A., Kurihara Toshihide, Tsubota Kazuo

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 118 ( 22 ) 2021.06

Lead author, Last author, Corresponding author, ISSN 0027-8424

Access to Document (DOI)

Violet light suppresses lens-induced myopia via neuropsin (OPN5) in mice.

Jiang X, Pardue MT, Mori K, Ikeda SI, Torii H, D'Souza S, Lang RA, Kurihara T, Tsubota K

Proceedings of the National Academy of Sciences of the United States of America 118 ( 22 ) 2021.06

Lead author, Last author, Corresponding author, ISSN 0027-8424

Access to Document (DOI)

Violet light suppresses lens-induced myopia via neuropsin (OPN5) in mice

Jiang X., Pardue M.T., Mori K., Ikeda S.I., Torii H., D'Souza S., Lang R.A., Kurihara T., Tsubota K.

Proceedings of the National Academy of Sciences of the United States of America (Proceedings of the National Academy of Sciences of the United States of America) 118 ( 22 ) 2021.06

Lead author, Last author, Corresponding author, ISSN 00278424

Myopia has become a major public health concern, particularly across much of Asia. It has been shown in multiple studies that outdoor activity has a protective effect on myopia. Recent reports have shown that short-wavelength visible violet light is the component of sunlight that appears to play an important role in preventing myopia progression in mice, chicks, and humans. The mechanism underlying this effect has not been understood. Here, we show that violet light prevents lens defocus-induced myopia in mice. This violet light effect was dependent on both time of day and retinal expression of the violet light sensitive atypical opsin, neuropsin (OPN5). These findings identify Opn5-expressing retinal ganglion cells as crucial for emmetropization in mice and suggest a strategy for myopia prevention in humans.

Access to Document (DOI)

Predicting keratoconus progression using deep learning

N Kato, H Masumoto, M Tanabe, C Sakai, K Negishi, H Torii, H Tabuchi, ...

Investigative Ophthalmology & Visual Science 62 (8), 769-769 62 ( 8 ) 2021.06

Lead author, Last author, Corresponding author, ISSN 0146-0404

Violet light suppresses lens-induced myopia via neuropsin (OPN5) in mice

Xiaoyan Jiang, Machelle T. Pardue, Kiwako Mori, Shin-ichi Ikeda, Hidemasa Torii, Shane D’Souza, Richard A. Lang, Toshihide Kurihara, Kazuo Tsubota

Proceedings of the National Academy of Sciences (Proceedings of the National Academy of Sciences) 118 ( 22 ) 2021.05

Lead author, Last author, Corresponding author, ISSN 00278424

<jats:title>Significance</jats:title>
<jats:p>
The increasing prevalence of myopia is a significant public health concern. Unfortunately, the mechanisms driving myopia remain elusive, limiting effective treatment options. This report identifies a refractive development pathway that requires
<jats:italic>Opn5</jats:italic>
-expressing retinal ganglion cells (RGCs). Stimulation of
<jats:italic>Opn5</jats:italic>
RGCs with short-wavelength violet light prevented experimental myopia in mice. Furthermore, this effect was dependent on the time of day, with evening exposure being sufficient to protect against experimental myopia. Thus, these studies suggest
<jats:italic>Opn5</jats:italic>
RGCs may contribute to the mechanisms of emmetropization and identify the OPN5 pathway as a potential target for the treatment of myopia.
</jats:p>

小児の近視予防に用いられる0.01%アトロピンの有効性と安全性について検討した2年無作為化プラセボ対照試験(Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study)

Hieda Osamu, Hiraoka Takahiro, Fujikado Takashi, Ishiko Satoshi, Hasebe Satoshi, Torii Hidemasa, Takahashi Hiroshi, Nakamura Yo, Sotozono Chie, Oshika Tetsuro, Morimoto Takeshi, Nishida Kohji, Nishikawa Noriko, Song Young-Seok, Tokutake Tomoki, Nishi Yasuyo, Shigeno Yuta, Kurihara Toshihide, Negishi Kazuno, Tsubota Kazuo, Ono Masafumi, Nakai Tomoko, Tan Donald, Tanaka Shiro, Kinoshita Shigeru, the ATOM-J.Study Group

Japanese Journal of Ophthalmology (シュプリンガー・ジャパン(株)) 65 ( 3 ) 315 - 325 2021.05

Lead author, Last author, Corresponding author, ISSN 0021-5155

日本人小児の近視予防に0.01%アトロピン点眼剤が有効かどうか検討した。本研究は多施設共同無作為化二重盲検プラセボ対照試験であり、6～12歳児168名をアトロピン点眼剤投与群84名(男児38名、女児46名、平均8.99±1.44歳)とプラセボ投与群84例(男児36名、女児48名、平均8.98±1.50歳)に割り付け、それぞれ24ヵ月間投与した。評価項目は等価球面度数(SE)と眼軸長(AL)の変化とした。全例におけるベースライン時のSEは平均-2.95D、ALは平均24.5mmであった。2週後、遠視への移行はみられず、これ以降全例で近視の進行がみられた。24ヵ月後におけるSEの平均変化はアトロピン投与群が-1.26D、プラセボ群が-1.48D、ALの平均変化はアトロピン投与群が0.63mm、プラセボ群が0.77mmであり、いずれも有意な群間差が認められた。また、両群とも眼圧に関して24ヵ月後に有意な変化はみられなかったが、アトロピン群において2週後と12週後に明所視虹彩径が有意に増大していた。試験期間中に生じた非重篤な有害事象として、アトロピン群に片麻痺性片頭痛1例、プラセボ群に視神経乳頭出血を認め、副作用としてアトロピン群に羞明1例、プラセボ群に近見障害1例がみられた。小児にみられる近視の進行予防に際して、0.01%アトロピン点眼剤は有効かつ安全であることが示された。

Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study

O Hieda, T Hiraoka, T Fujikado, S Ishiko, S Hasebe, H Torii, H Takahashi, ...

Japanese Journal of Ophthalmology 65, 315-325 (Japanese Journal of Ophthalmology) 65 ( 3 ) 315 - 325 2021.05

Lead author, Last author, Corresponding author, ISSN 0021-5155

Purpose: Atropine eye drops prevent the progression of myopia, but their use has not been tested in the Japanese schoolchildren population. Here, we evaluate the efficacy and safety of 0.01% atropine eye drops for myopia control in Japanese children. Study design: Multicenter (7 university hospitals), randomized, double-masked, placebo-controlled trial. Methods: Participants were 171 Japanese schoolchildren aged 6 to 12 years, with progressive myopia, spherical equivalence (SE) of −1.00 to −6.00 diopters (D), and astigmatism of ≤1.5 D. They were randomized to receive either 0.01% atropine (n=85) or placebo (n=86) eye drops once nightly OU for 24 months. Primary and secondary efficacy endpoints were changes in SE and axial length (AL), respectively, from baseline to month 24. Results: Data from 168 subjects were analyzed. At month 24, compliance was similar in both groups (atropine: 83.3%; placebo: 85.7%). The least squares mean change in SE and AL from baseline were, respectively, −1.26 D (95% confidence interval [CI]: −1.35, −1.17) and 0.63 mm (0.59, 0.67) for atropine and −1.48 D (− 1.57, −1.39) and 0.77 mm (0.73, 0.81) for placebo. Inter-group differences were 0.22 D (95% CI: 0.09, 0.35; P < 0.001) for SE and − 0.14 mm (−0.20, −0.08; P < 0.001) for AL. Three patients experienced mild allergic conjunctivitis side effects, with no inter-group difference in incidence (atropine: 2.4%; 2/84 patients; placebo: 1.4%; 1/84 patients). Conclusion: With good compliance, 0.01% atropine is effective and safe for preventing the progression of childhood myopia.

Access to Document (DOI)

Predicting keratoconus progression and need for corneal crosslinking using deep learning

N Kato, H Masumoto, M Tanabe, C Sakai, K Negishi, H Torii, H Tabuchi, ...

Journal of clinical medicine 10 (4), 844 (Journal of Clinical Medicine) 10 ( 4 ) 1 - 9 2021.02

Lead author, Last author, Corresponding author, ISSN 2077-0383

We aimed to predict keratoconus progression and the need for corneal crosslinking (CXL) using deep learning (DL). Two hundred and seventy-four corneal tomography images taken by Pentacam HR® (Oculus, Wetzlar, Germany) of 158 keratoconus patients were examined. All patients were examined two times or more, and divided into two groups; the progression group and the non-progression group. An axial map of the frontal corneal plane, a pachymetry map, and a combination of these two maps at the initial examination were assessed according to the patients’ age. Training with a convolutional neural network on these learning data objects was conducted. Ninety eyes showed progression and 184 eyes showed no progression. The axial map, the pachymetry map, and their combination combined with patients’ age showed mean AUC values of 0.783, 0.784, and 0.814 (95% confidence interval (0.721–0.845) (0.722–0.846), and (0.755–0.872), respectively), with sen-sitivities of 87.8%, 77.8%, and 77.8% ((79.2–93.7), (67.8–85.9), and (67.8–85.9)) and specificities of 59.8%, 65.8%, and 69.6% ((52.3–66.9), (58.4–72.6), and (62.4–76.1)), respectively. Using the proposed DL neural network model, keratoconus progression can be predicted on corneal tomography maps combined with patients’ age.

Access to Document (DOI)

特集近視コントロールアップデート１　世界の近視の激増(日本も含む)

羽入田明子, 鳥居秀成

眼科 (金原出版) 63 ( 1 ) 3 - 14 2021.01

Lead author, Last author, Corresponding author, ISSN 00164488

　 Previous page - Next page 　